Changmao Biotech (00954) announced interim results. Shareholders' losses of 4.932 million yuan decreased by 80.88% year-on-year

According to the Zhitong Finance App, Changmao Biotech (00954) announced interim results for the six months ended June 30, 2026. The group obtained revenue of 290 million yuan, an increase of 6.34% over the previous year; losses attributable to the Company's shareholders during the period were 4.932 million yuan, a year-on-year decrease of 80.88%; and a loss of 0.009 yuan per share.

The first half of the year recorded a net loss attributable to the Company's shareholders of approximately RMB 4.932 million, but the net loss was significantly narrowed by about 81% compared to RMB 25.79 million in the same period last year. The quality of operations improved markedly, and fundamentals continued to improve.